BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Memory Pharmaceuticals (MEMY) to Present at the Rodman & Renshaw Annual Global Investment Conference


11/7/2008 8:51:15 AM

MONTVALE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that Michael Smith, Chief Financial Officer and Head of Business Development, will provide a company update at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, November 11, 2008 at 11:10 a.m. EST at the New York Palace Hotel, in New York City.

Interested parties may access the live webcast of the presentation by visiting the "Investors" section of Memory Pharmaceuticals' website at http://www.memorypharma.com. Archived versions of the webcast will be available at the same location for one week following the presentation.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

CONTACT: Jzaneen Lalani, General Counsel of Memory Pharmaceuticals Corp.,
+1-201-802-7249; or Laura Perry of LMP Investor Relations Inc.,
+1-646-719-1055, of Memory Pharmaceuticals Corp.

Web site: http://www.memorypharma.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES